JPH0557015A - Adsorbent and sterilizing method therefor - Google Patents
Adsorbent and sterilizing method thereforInfo
- Publication number
- JPH0557015A JPH0557015A JP3250191A JP25019191A JPH0557015A JP H0557015 A JPH0557015 A JP H0557015A JP 3250191 A JP3250191 A JP 3250191A JP 25019191 A JP25019191 A JP 25019191A JP H0557015 A JPH0557015 A JP H0557015A
- Authority
- JP
- Japan
- Prior art keywords
- adsorbent
- aqueous solution
- sulfate
- pressure steam
- sulfated polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003463 adsorbent Substances 0.000 title claims abstract description 44
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 32
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 23
- 239000005017 polysaccharide Substances 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000000746 purification Methods 0.000 claims abstract description 9
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 24
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001179 sorption measurement Methods 0.000 abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 150000004804 polysaccharides Chemical class 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 17
- 229920002307 Dextran Polymers 0.000 description 13
- 229960002086 dextran Drugs 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 12
- 235000010262 sodium metabisulphite Nutrition 0.000 description 12
- 229960000633 dextran sulfate Drugs 0.000 description 10
- -1 dextran sulfate Chemical class 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102400000269 Amyloid protein A Human genes 0.000 description 1
- 101710144835 Amyloid protein A Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
Landscapes
- Apparatus For Disinfection Or Sterilisation (AREA)
- External Artificial Organs (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、血液中の有害成分を吸
着除去するための硫酸化多糖類を表面に有する血液浄化
用吸着剤とその滅菌方法に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an adsorbent for blood purification having on its surface a sulfated polysaccharide for adsorbing and removing harmful components in blood, and a sterilizing method thereof.
【0002】[0002]
【従来の技術】血液中の有害成分除去の目的に、該有害
成分に対して親和性のある物質、即ちリガンドを共有結
合によって水不溶性担体に固定した吸着剤を、臨床的に
利用しようとする試みが成されている。2. Description of the Related Art For the purpose of removing harmful components in blood, a substance having an affinity for the harmful components, that is, an adsorbent in which a ligand is immobilized on a water-insoluble carrier by a covalent bond, is clinically utilized. Attempts have been made.
【0003】これら吸着剤を臨床に用いるためには滅菌
が不可欠である。この滅菌方法としては取扱い性、安全
性の点で高圧蒸気滅菌が好ましい。しかしこれら吸着剤
を高圧蒸気滅菌するとリガンドの失活や脱離が起こり、
その結果、吸着剤の有する除去性能の大幅な低下を伴
い、かつ臨床施行時の安全性の点でも問題がある。特
に、デキストラン硫酸などの硫酸化多糖類では、高圧蒸
気滅菌時の熱による硫酸化多糖類と水不溶性担体との共
有結合部分の開裂と硫酸化多糖類分子自体の分解、その
分解の過程で生じた硫酸化合物により更に加速的に自己
分解が進んでしまうと考えられる。Sterilization is indispensable for clinical use of these adsorbents. As the sterilization method, high-pressure steam sterilization is preferable from the viewpoints of handleability and safety. However, high pressure steam sterilization of these adsorbents causes deactivation and desorption of ligands,
As a result, the removal performance of the adsorbent is greatly reduced, and there is a problem in safety in clinical practice. Particularly, in the case of sulfated polysaccharides such as dextran sulfate, the covalent bond between the sulfated polysaccharide and the water-insoluble carrier is cleaved by heat during high-pressure steam sterilization, the sulfated polysaccharide molecule itself is decomposed, and occurs in the process of its decomposition. It is considered that the sulfuric acid compound further accelerates the self-decomposition.
【0004】ところで硫酸化多糖類を表面に有する吸着
剤の高圧蒸気滅菌をクエン酸、リン酸、酢酸、ホウ酸、
酒石酸、炭酸、マレイン酸、グリシンの内の少なくとも
1種を用いたpH5〜9の緩衝液中で行うことによって
硫酸化多糖類の分解を少なくしようとする試みがある
(特開昭61−100261号)。 しかしながら上記方法はなるほど生成された硫酸化合物
によるpH低下に起因する自己分解は防止し得るが、熱
そのものによる分解を防止するものではなく、かなりの
性能の低下とリガンドの脱離があり大きな問題であっ
た。By the way, high pressure steam sterilization of an adsorbent having a sulfated polysaccharide on its surface is carried out by citric acid, phosphoric acid, acetic acid, boric acid,
There has been an attempt to reduce the decomposition of sulfated polysaccharides by carrying out in a buffer solution of at least one of tartaric acid, carbonic acid, maleic acid and glycine at pH 5 to 9 (JP-A-61-100261). ). However, although the above-mentioned method can prevent self-decomposition due to pH decrease due to the generated sulfuric acid compound, it does not prevent decomposition due to heat itself, and there is a considerable decrease in performance and desorption of ligand, which is a serious problem. there were.
【0005】[0005]
【発明が解決しようとする課題】本発明者らがより優れ
た滅菌方法を見いだすべく鋭意研究した結果、硫酸化多
糖類を表面に有する血液浄化用吸着剤を高圧蒸気滅菌す
るに当たり、ピロ亜硫酸または/及びその塩を0.00
1〜10%含む水溶液中で行うことによって吸着剤の有
する除去性能の低下を抑制できる、という画期的な事実
を見い出し、除去性能の低下が無い、安全性にも優れた
吸着剤を発明するに至った。DISCLOSURE OF THE INVENTION As a result of intensive studies conducted by the present inventors to find a better sterilization method, it was found that pyrosulfite or / And its salt 0.00
We have found an epoch-making fact that the removal performance of adsorbents can be suppressed from decreasing by carrying out in an aqueous solution containing 1 to 10%, and we invent an adsorbent that is free from deterioration of removal performance and excellent in safety. Came to.
【0006】[0006]
【課題を解決するための手段】すなわち本発明の要旨
は、ピロ亜硫酸または/及びその塩を0.001〜10
%含み、pHが5〜9.5の範囲に調整された水溶液中
で高圧蒸気滅菌を行うことを特徴とする、硫酸化多糖類
を表面に有する血液浄化用吸着剤の滅菌方法、及びこの
滅菌方法によって得られた血液浄化用吸着剤にある。That is, the gist of the present invention is to provide pyrosulfite or / and its salt in an amount of 0.001-10.
%, And high-pressure steam sterilization in an aqueous solution whose pH is adjusted to a range of 5 to 9.5, and a method for sterilizing an adsorbent for blood purification having a sulfated polysaccharide on its surface, and this sterilization In the adsorbent for blood purification obtained by the method.
【0007】本発明者らが種々研究した結果によると、
ピロ亜硫酸または/及びその塩は、高圧蒸気滅菌時の熱
による硫酸化多糖類と水不溶性担体との共有結合部分の
開裂と、硫酸化多糖類分子自体の分解の両者に対して防
止効果があると考えられる。According to the results of various studies by the present inventors,
Pyrosulfurous acid and / or its salt have an effect of preventing both the cleavage of the covalent bond between the sulfated polysaccharide and the water-insoluble carrier due to heat during high-pressure steam sterilization and the decomposition of the sulfated polysaccharide molecule itself. it is conceivable that.
【0008】本発明をより詳細に説明すると、ピロ亜硫
酸または/及びその塩の濃度は0.001〜10%であ
ることが望ましい。更に望ましくは0.01〜2%の範
囲がよい。この時、アルカリ性物質によってpH5〜
9.5であることが低pHでの自己分解を防止するため
に有効であり、この両者の組み合わせではじめて優れた
滅菌方法となり得る。To explain the present invention in more detail, it is desirable that the concentration of pyrosulfite or / and its salt is 0.001 to 10%. More preferably, the range is 0.01 to 2%. At this time, depending on the alkaline substance,
A value of 9.5 is effective for preventing self-decomposition at low pH, and an excellent sterilization method can be achieved only by combining these two.
【0009】pHが5〜9.5であることとは滅菌直後
の水溶液のpHが5〜9.5であることを言う。滅菌前
のpHは、5〜9.5であることが望ましいが、吸着剤
を水溶液に浸漬後速やかに滅菌を行う場合は必ずしも限
定されない。但し、pH4.5以下では硫酸化多糖類の
分解が速やかであるため滅菌前のpHは5以上であるこ
とが好ましい。The pH of 5 to 9.5 means that the pH of the aqueous solution immediately after sterilization is 5 to 9.5. The pH before sterilization is preferably 5 to 9.5, but is not necessarily limited to the case where the adsorbent is immersed in an aqueous solution and then rapidly sterilized. However, the pH before sterilization is preferably 5 or higher because the sulfated polysaccharide is rapidly decomposed at pH 4.5 or lower.
【0010】水溶液のpHを5〜9.5とするには、ア
ルカリ金属またはアルカリ土類金属の炭酸化物、水酸化
物、或いは炭酸水素化合物など、例えば炭酸ナトリウ
ム、炭酸水素ナトリウム、水酸化ナトリウム、水酸化カ
リウムなどの塩基性物質を該水溶液中に加えることによ
ってできる。この時の至適な塩基性物質の濃度はピロ亜
硫酸または/及びその塩の濃度によって変わり、必ずし
も特定できないが、通常0.001〜5%が好ましく用
いることができ、特により好ましい範囲をあげるならば
0.005〜1.5%である。To adjust the pH of the aqueous solution to 5 to 9.5, alkali metal or alkaline earth metal carbonates, hydroxides, or hydrogen carbonate compounds, such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, This can be done by adding a basic substance such as potassium hydroxide into the aqueous solution. The optimum concentration of the basic substance at this time varies depending on the concentration of pyrosulfurous acid or / and its salt and cannot be specified. However, usually 0.001 to 5% can be preferably used, and if a particularly preferable range is mentioned, For example, it is 0.005 to 1.5%.
【0011】本発明者らの研究によると、この中で特に
炭酸ナトリウムと炭酸水素ナトリウムが取扱い性も考慮
して最も良好であった。あえて最も良好な例をあげる
と、ピロ亜硫酸ナトリウム0.01〜0.2%、炭酸ナ
トリウム0.005〜0.2%である。According to the research conducted by the present inventors, sodium carbonate and sodium hydrogencarbonate were the best among these, considering the handling property. The most preferable examples are 0.01-0.2% sodium pyrosulfite and 0.005-0.2% sodium carbonate.
【0012】本発明でいう硫酸化多糖類を表面に有する
血液浄化用吸着剤とは、硫酸化多糖類を共有結合を介し
て水不溶性担体に不溶化したものである。水不溶性担体
の形状としては球状、粒状、糸状、中空糸状、平膜状な
どいずれも有効に使用できる。この中で球状又は粒状の
ものが、単位容積あたりの吸着面積を多くとれるので最
も好ましい。The adsorbent for blood purification having a sulfated polysaccharide on its surface as used in the present invention is an adsorbent in which a sulfated polysaccharide is insolubilized in a water-insoluble carrier through a covalent bond. As the shape of the water-insoluble carrier, any of spherical shape, granular shape, thread shape, hollow fiber shape, flat membrane shape and the like can be effectively used. Among these, spherical or granular ones are most preferable because they can have a large adsorption area per unit volume.
【0013】球状又は粒状の平均粒径は、10〜2,5
00μmのものが使いやすいが、25〜1,000μm
の範囲のものが好ましい。水不溶性担体は、有害成分の
吸着面積を大きくとれ、実用的な吸着能力を出せるとい
う観点から、多孔性であることが好ましい。多孔性の排
除限界分子量は、吸着しようとする有害成分の分子量に
よって異なるが、1×104 以上、1×108 以下のも
のが好ましい。更に限定するならば、1×105 以上、
5×107 以下のものがより好ましい。The spherical or granular average particle size is 10 to 2,5.
It is easy to use the one of 00 μm, but it is 25-1,000 μm
The range of is preferable. The water-insoluble carrier is preferably porous from the viewpoint that a large adsorption area for harmful components can be obtained and a practical adsorption capacity can be obtained. The exclusion limit molecular weight of porosity depends on the molecular weight of the harmful component to be adsorbed, but is preferably 1 × 10 4 or more and 1 × 10 8 or less. To further limit, 1 × 10 5 or more,
It is more preferably 5 × 10 7 or less.
【0014】水不溶性担体の具体例を挙げると、例えば
アガロース、デキストラン、ポリアクリルアミド等から
なる軟質ゲル、メチルメタクリレート、ポリビニルアル
コール、スチレン、ジビニルベンゼン、ビニルエーテ
ル、無水マレイン酸、ポリアミド等の内の一つまたは複
数を構成成分とする合成高分子、または/及びセルロー
ス等の天然高分子を原料とする多孔質ポリマーからなる
硬質ゲルなどである。更に、ヒドロキシエチルメタクリ
レート、ヒドロキシエチルアクリレート等のヒドロキシ
基を有する高分子材料、ビニルアミン、ジメチルアミノ
エチル(メタ)アクリレート等の塩基性含窒素官能基を
有する単量体と塩基性含窒素官能基を有さない重合性単
量体との共重合体、スルフォン酸基、カルボン酸基等の
負電荷官能基を有する高分子材料、セグメント化ポリウ
レタン、セグメント化ポリエステル等のブロック共重合
体、ポリエチレンオキサイド鎖を有する単量体と他の重
合性単量体との共重合体の様なグラフト共重合体等の表
面層を有していても良い。Specific examples of the water-insoluble carrier include, for example, one of soft gels made of agarose, dextran, polyacrylamide, etc., methyl methacrylate, polyvinyl alcohol, styrene, divinylbenzene, vinyl ether, maleic anhydride, polyamide, etc. Alternatively, a synthetic polymer having a plurality of constituents, and / or a hard gel made of a porous polymer obtained from a natural polymer such as cellulose as a raw material. Further, a polymer material having a hydroxy group such as hydroxyethyl methacrylate and hydroxyethyl acrylate, a monomer having a basic nitrogen-containing functional group such as vinylamine and dimethylaminoethyl (meth) acrylate, and a basic nitrogen-containing functional group are included. A copolymer with a polymerizable monomer, a polymer material having a negatively charged functional group such as a sulfonic acid group or a carboxylic acid group, a segmented polyurethane, a block copolymer such as a segmented polyester, or a polyethylene oxide chain. It may have a surface layer such as a graft copolymer such as a copolymer of the monomer having it and another polymerizable monomer.
【0015】これらの内、硬質ゲルが体液の流通性の観
点より好ましく用いられる。更により好ましくはポリビ
ニルアルコール等からなる合成高分子の硬質ゲルが、ゲ
ル表面に活性基を比較的容易に得られるため実用状好ま
しい。硫酸化多糖類と共有結合する水不溶性担体表面の
活性基は、硫酸化多糖類の水酸基、カルボキシル基など
の活性水素を有する反応性基と置換または/及び付加反
応できるものであれば良い。Of these, hard gels are preferably used from the viewpoint of the flowability of body fluids. Still more preferably, a synthetic polymer hard gel made of polyvinyl alcohol or the like is preferable for practical use because an active group can be relatively easily obtained on the gel surface. The active group on the surface of the water-insoluble carrier that is covalently bonded to the sulfated polysaccharide may be any group that can be substituted or / and addition-reacted with a reactive group having an active hydrogen such as a hydroxyl group or a carboxyl group of the sulfated polysaccharide.
【0016】水不溶性担体に活性基を得る方法の一例と
してはハロゲン化シアン法、エピクロルヒドリン法、ビ
スエポキシド法、ブロモアセチルブロミド法等が知られ
ている。具体的にはアミノ基、カルボキシル基、ヒドロ
キシル基、チオール基、酸無水物基、サクシニルイミド
基、塩素基、アルデヒド基、アミド基、エポキシ基など
があげられる。Known examples of methods for obtaining an active group on a water-insoluble carrier include a cyanogen halide method, an epichlorohydrin method, a bisepoxide method, and a bromoacetyl bromide method. Specific examples thereof include an amino group, a carboxyl group, a hydroxyl group, a thiol group, an acid anhydride group, a succinylimide group, a chlorine group, an aldehyde group, an amide group and an epoxy group.
【0017】この中で加熱滅菌時の安定性よりエピクロ
ルヒドリン法などで誘導されるエポキシ基が特に好まし
い例としてあげられる。以上の活性基を介して共有結合
される硫酸化多糖類とは、その分子中に硫酸基を持つ多
糖類であって、ヘパリン、デキストラン硫酸、コンドロ
イチン硫酸、コンドロイチンポリ硫酸、ヘパラン硫酸、
ケラタン硫酸、ヘパリチン硫酸、キシラン硫酸、カロニ
ン硫酸、セルロース硫酸、キチン硫酸、キトサン硫酸、
ペクチン硫酸、イヌリン硫酸、アルギン酸硫酸、グリコ
ーゲン硫酸、ポリラクトース硫酸、カラゲニン硫酸、デ
ンプン硫酸、ポリグルコース硫酸、ラミラリン硫酸、ガ
ラクタン硫酸、レバン硫酸、メペサルフェート等があげ
られる。この中で特に臨床での実用性の点より最も好ま
しい例としてヘパリンやデキストラン硫酸があげられ
る。Of these, an epoxy group derived from the epichlorohydrin method or the like is particularly preferable because of its stability during heat sterilization. The sulfated polysaccharide covalently bound through the above active group is a polysaccharide having a sulfate group in its molecule, heparin, dextran sulfate, chondroitin sulfate, chondroitin polysulfate, heparan sulfate,
Keratan sulfate, heparitin sulfate, xylan sulfate, caronine sulfate, cellulose sulfate, chitin sulfate, chitosan sulfate,
Examples thereof include pectin sulfate, inulin sulfate, alginate sulfate, glycogen sulfate, polylactose sulfate, carrageenin sulfate, starch sulfate, polyglucose sulfate, ramillarin sulfate, galactan sulfate, levan sulfate, and mepesulfate. Of these, heparin and dextran sulfate are the most preferable examples from the viewpoint of clinical practicality.
【0018】これらの硫酸化多糖類の分子量はいずれの
分子量であっても良いが、あえてあげるならばリガンド
としての性能の点より分子量5,000以上のものが特
によい。The molecular weight of these sulfated polysaccharides may be any molecular weight, but if it is dared to say, a molecular weight of 5,000 or more is particularly preferable from the viewpoint of performance as a ligand.
【0019】以上の、ピロ亜硫酸または/及びその塩を
0.001〜10%含む水溶液中に充填された、硫酸化
多糖類を表面に有する血液浄化用吸着剤の用途として
は、低密度または/及び極低密度リポ蛋白質、スルファ
チド付着性蛋白質、活性化補体成分、アミロイド蛋白
A、免疫複合体、抗DNA抗体やリウマチ因子等の自己
抗体または/及び該自己抗体を生産する免疫B細胞、免
疫グロブリンL鎖、血液凝固第VIII因子、血液凝固第IX
因子、β2 ミクログロブリン等があげられる。この中で
低密度または/及び極低密度リポ蛋白質の吸着剤として
の用途が臨床上の有用性が高い。The above-mentioned adsorbent for blood purification having a sulfated polysaccharide on the surface, which is filled in an aqueous solution containing 0.001 to 10% of pyrosulfurous acid and / or its salt, has a low density or / And extremely low density lipoprotein, sulfatide adhesion protein, activated complement component, amyloid protein A, immune complex, autoantibody such as anti-DNA antibody and rheumatoid factor, and / or immune B cell producing the autoantibody, immunity Globulin L chain, blood coagulation factor VIII, blood coagulation factor IX
Factor, β 2 microglobulin and the like. Among them, the use of low density and / or very low density lipoprotein as an adsorbent is highly clinically useful.
【0020】[0020]
【発明の効果】本発明の、ピロ亜硫酸または/及びその
塩を0.001〜10%含む水溶液中で滅菌することに
よって、これまで滅菌操作時に発生していた性能の低下
を防止でき、しかもリガンドである硫酸化多糖類の脱離
も少ない、優れた品質の吸着剤が得られる。By sterilizing the present invention in an aqueous solution containing 0.001 to 10% of pyrosulfurous acid and / or a salt thereof, it is possible to prevent the deterioration of the performance which has occurred during the sterilization operation up to now, and the ligand It is possible to obtain an adsorbent of excellent quality with little desorption of sulfated polysaccharides.
【0021】[0021]
【実施例】以下に具体例をあげて説明するが、本発明は
これらに限定されるものではない。EXAMPLES The present invention will be described below with reference to specific examples, but the present invention is not limited thereto.
【0022】実施例1.トリアリルイソシアヌレートを
架橋剤として用い、リン酸緩衝水溶液中で酢酸ビニルを
懸濁重合して、ポリビニルアルコール共重合体を得た。
得られたポリビニルアルコール共重合体を、水不溶性担
体として用いた。この水不溶性担体は、平均粒径100
μm、単位重量あたりのビニルアルコール単位(qO
H)が6.0meq/g、排除限界分子量5x106 で
あった。Example 1. Using triallyl isocyanurate as a cross-linking agent, suspension polymerization of vinyl acetate in a phosphate buffer aqueous solution was performed to obtain a polyvinyl alcohol copolymer.
The obtained polyvinyl alcohol copolymer was used as a water-insoluble carrier. This water-insoluble carrier has an average particle size of 100.
μm, vinyl alcohol unit per unit weight (qO
H) was 6.0 meq / g, and the exclusion limit molecular weight was 5 × 10 6 .
【0023】次にエステル交換して水で十分に洗浄した
後、ジメチルスルフォキシドと水酸化ナトリウム水溶液
の混合液中でエピクロルヒドリンを反応させて、エポキ
シ活性化担体を得た。このエポキシ活性化担体に、エポ
キシ基を介して、分子量500,000、硫黄含量1
8.2wt%のデキストラン硫酸を共有結合させて、デ
キストラン硫酸固定の吸着剤を得た。この吸着剤に固定
されたデキストラン硫酸量は、吸着剤1mlあたり5.
9mgであった。After transesterification and thorough washing with water, epichlorohydrin was reacted in a mixed solution of dimethyl sulfoxide and an aqueous sodium hydroxide solution to obtain an epoxy activated carrier. This epoxy-activated carrier has a molecular weight of 500,000 and a sulfur content of 1 via an epoxy group.
A dextran sulfate-immobilized adsorbent was obtained by covalently bonding 8.2 wt% of dextran sulfate. The amount of dextran sulfate fixed on this adsorbent was 5.
It was 9 mg.
【0024】この吸着剤10mlを取り、ピロ亜硫酸ナ
トリウム0.02%、炭酸ナトリウム0.016%を含
む水溶液100ml中で、121℃で30分間高圧蒸気
滅菌を行った。この時、滅菌前後のpHと吸着剤1ml
あたりのデキストラン硫酸固定量、コレステロール吸着
除去性能を測定した。コレステロール吸着性能は、コレ
ステロール濃度410mg/d1の人血漿を用いて測定
した。結果を表1に示す。10 ml of this adsorbent was taken and subjected to high-pressure steam sterilization at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.02% of sodium pyrosulfite and 0.016% of sodium carbonate. At this time, pH before and after sterilization and 1 ml of adsorbent
The fixed amount of dextran sulfate and the adsorption / removal performance of cholesterol were measured. The cholesterol adsorption performance was measured using human plasma with a cholesterol concentration of 410 mg / d1. The results are shown in Table 1.
【0025】[0025]
【表1】 [Table 1]
【0026】実施例2.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.06%、炭酸ナトリウム0.03%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。Example 2. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing sodium pyrosulfite 0.06% and sodium carbonate 0.03%.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.
【0027】実施例3.実施例1得られたデキストラン
硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.05%、炭酸ナトリウム0.06%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。Example 3. Example 1 10 ml of the obtained dextran sulfate-fixed adsorbent was added to an aqueous solution 1 containing 0.05% sodium pyrosulfite and 0.06% sodium carbonate.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.
【0028】実施例4.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.24%、炭酸ナトリウム0.09%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。Example 4. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing sodium pyrosulfite 0.24% and sodium carbonate 0.09%.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.
【0029】実施例5.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.12%、炭酸ナトリウム0.06%含む水溶液10
0ml中で、121℃で30分間高圧蒸気滅菌を行い、
実施例1と同様吸着性能の測定を行った。結果を表1に
示す。Example 5. 10 ml of an aqueous solution containing 0.12% of sodium pyrosulfite and 0.06% of sodium carbonate was added to 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1.
Perform high-pressure steam sterilization in 0 ml at 121 ° C for 30 minutes,
The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.
【0030】実施例6.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
1.00%、炭酸ナトリウム0.50%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様吸着性能の測定を行った。結果を表
1に示す。Example 6. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was treated with an aqueous solution 1 containing sodium pyrosulfite (1.00%) and sodium carbonate (0.50%).
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.
【0031】実施例7.水不溶性担体として、平均粒子
系80μm、排除限界分子量500万のセルロースゲル
(チッソ(株)製)を用い、実施例1と同様にしてデキ
ストラン硫酸固定の吸着剤を得た。Example 7. A cellulose gel having an average particle size of 80 μm and an exclusion limit molecular weight of 5,000,000 (manufactured by Chisso Corporation) was used as a water-insoluble carrier, and a dextran sulfate-fixed adsorbent was obtained in the same manner as in Example 1.
【0032】この吸着剤に固定されたデキストラン硫酸
量は、吸着剤1mlあたり0.62mgであった。この
でデキストラン硫酸固定の吸着剤10mlを、ピロ亜硫
酸ナトリウム0.12%、炭酸ナトリウム0.06%を
含む水溶液100ml中で、121℃で30分間高圧蒸
気滅菌を行い、実施例1と同様吸着性能の測定を行っ
た。結果を表1に示す。The amount of dextran sulfate fixed on this adsorbent was 0.62 mg per 1 ml of the adsorbent. Then, 10 ml of the dextran sulfate-fixed adsorbent was subjected to high-pressure steam sterilization at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing sodium pyrosulfite 0.12% and sodium carbonate 0.06%, and the adsorption performance was the same as in Example 1. Was measured. The results are shown in Table 1.
【0033】比較例1.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、ピロ亜硫酸ナトリウム
0.24%、炭酸ナトリウム0.06%を含む水溶液1
00ml中で、121℃で30分間高圧蒸気滅菌を行
い、実施例1と同様の吸着性能の測定を行った。結果を
表1に示す。Comparative Example 1. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was used as an aqueous solution 1 containing 0.24% of sodium pyrosulfite and 0.06% of sodium carbonate.
High-pressure steam sterilization was carried out for 30 minutes at 121 ° C. in 00 ml, and the adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.
【0034】比較例2.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを用いて、リン酸2水素カ
リウム0.27%、リン酸水素2ナトリウム0.67%
を含む水溶液100ml中で、121℃で30分間高圧
蒸気滅菌を行い、実施例1と同様吸着性能の測定を行っ
た。結果を表1に示す。Comparative Example 2. Using 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1, potassium dihydrogen phosphate 0.27%, disodium hydrogen phosphate 0.67%
High-pressure steam sterilization was carried out at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing, and the adsorption performance was measured as in Example 1. The results are shown in Table 1.
【0035】比較例3.実施例1で得られたデキストラ
ン硫酸固定の吸着剤10mlを、リン酸2水素カリウム
0.65%、リン酸水素2ナトリウム0.29%を含む
水溶液100ml中で、121℃で30分間高圧蒸気滅
菌を行い、実施例1と同様吸着性能の測定を行った。結
果を表1に示す。Comparative Example 3. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 1 was autoclaved at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.65% potassium dihydrogen phosphate and 0.29% disodium hydrogen phosphate. The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.
【0036】比較例4.実施例7で得られたデキストラ
ン硫酸固定の吸着剤10mlを、リン酸2水素カリウム
0.27%、リン酸水素2ナトリウム0.67%を含む
水溶液100ml中で、121℃で30分間高圧蒸気滅
菌を行い、実施例1と同様吸着性能の測定を行った。結
果を表1に示す。Comparative Example 4. 10 ml of the dextran sulfate-fixed adsorbent obtained in Example 7 was autoclaved at 121 ° C. for 30 minutes in 100 ml of an aqueous solution containing 0.27% potassium dihydrogen phosphate and 0.67% disodium hydrogen phosphate. The adsorption performance was measured in the same manner as in Example 1. The results are shown in Table 1.
【0037】ピロ亜硫酸ナトリウムが存在し、且つpH
が5〜9.5の範囲にある場合には、デキストラン硫酸
固定量とコレステロール吸着除去性能共に、滅菌前後で
ほとんど変化はみられなかった。これに対してピロ亜硫
酸ナトリウムが存在しない例では、pHが5〜9.5の
範囲にある場合でもデキストラン硫酸固定量とコレステ
ロール吸着除去性能共に、滅菌前後で低下がみられた。
更にピロ亜硫酸ナトリウムが存在してもpHが5〜9.
5の範囲に無い場合は、やはりデキストラン硫酸固定量
とコレステロール吸着除去性能共に、滅菌前後で低下が
みられた。Sodium pyrosulfite is present and pH
In the range of 5 to 9.5, there was almost no change in dextran sulfate fixed amount and cholesterol adsorption / removal performance before and after sterilization. On the other hand, in the example in which sodium pyrosulfite was not present, both the fixed amount of dextran sulfate and the adsorption / removal performance of cholesterol were decreased before and after sterilization even when the pH was in the range of 5 to 9.5.
Furthermore, even if sodium pyrosulfite is present, the pH is 5-9.
When it was not within the range of 5, the dextran sulfate fixed amount and the cholesterol adsorption / removal performance were also decreased before and after sterilization.
Claims (8)
01〜10%含み、pHが5〜9.5の範囲に調整され
た水溶液中で高圧蒸気滅菌を行うことを特徴とする、硫
酸化多糖類を表面に有する血液浄化用吸着剤の滅菌方
法。1. Pyrosulfurous acid or / and its salt is 0.0
A method for sterilizing an adsorbent for blood purification having a sulfated polysaccharide on the surface, which comprises performing high-pressure steam sterilization in an aqueous solution containing 01 to 10% and having a pH adjusted to a range of 5 to 9.5.
性物質が0.001〜5%含まれる請求項1記載の吸着
剤の滅菌方法。2. The method for sterilizing an adsorbent according to claim 1, wherein the aqueous solution contains 0.001 to 5% of at least one alkaline substance.
ルカリ土類金属からなる化合物の少なくとも1種である
請求項2記載の吸着剤の滅菌方法。3. The method for sterilizing an adsorbent according to claim 2, wherein the alkaline substance is at least one compound selected from alkali metals and alkaline earth metals.
水素ナトリウム、水酸化ナトリウム、水酸化カリウムの
少なくとも1種である請求項2記載の吸着剤の滅菌方
法。4. The method for sterilizing an adsorbent according to claim 2, wherein the alkaline substance is at least one of sodium carbonate, sodium hydrogen carbonate, sodium hydroxide and potassium hydroxide.
01〜10%含み、pHが5〜9.5の範囲に調整され
た水溶液中で高圧蒸気滅菌を行ったことを特徴とする、
硫酸化多糖類を表面に有する血液浄化用吸着剤。5. The amount of pyrosulfurous acid and / or its salt added to 0.0
High pressure steam sterilization was performed in an aqueous solution containing 01 to 10% and having a pH adjusted to a range of 5 to 9.5,
An adsorbent for blood purification having a sulfated polysaccharide on the surface.
性物質が0.001〜5%含まれる請求項5記載の吸着
剤。6. The adsorbent according to claim 5, wherein the aqueous solution contains 0.001 to 5% of at least one alkaline substance.
ルカリ土類金属からなる化合物の少なくとも1種である
請求項6記載の吸着剤。7. The adsorbent according to claim 6, wherein the alkaline substance is at least one compound selected from the group consisting of alkali metals and alkaline earth metals.
水素ナトリウム、水酸化ナトリウム、水酸化カリウムの
少なくとも1種である請求項6記載の吸着剤。8. The adsorbent according to claim 6, wherein the alkaline substance is at least one of sodium carbonate, sodium hydrogen carbonate, sodium hydroxide and potassium hydroxide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3250191A JPH0557015A (en) | 1991-09-04 | 1991-09-04 | Adsorbent and sterilizing method therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3250191A JPH0557015A (en) | 1991-09-04 | 1991-09-04 | Adsorbent and sterilizing method therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0557015A true JPH0557015A (en) | 1993-03-09 |
Family
ID=17204171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3250191A Pending JPH0557015A (en) | 1991-09-04 | 1991-09-04 | Adsorbent and sterilizing method therefor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0557015A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582386B2 (en) | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
US6706008B2 (en) | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
WO2004022111A1 (en) * | 2002-09-05 | 2004-03-18 | Mitra Medical Technology Ab | New composition use and method |
US6884228B2 (en) | 2001-03-06 | 2005-04-26 | Baxter International Inc. | Automated system adaptable for use with different fluid circuits |
JP2008544847A (en) * | 2005-07-06 | 2008-12-11 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Method for producing separation matrix |
-
1991
- 1991-09-04 JP JP3250191A patent/JPH0557015A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582386B2 (en) | 2001-03-06 | 2003-06-24 | Baxter International Inc. | Multi-purpose, automated blood and fluid processing systems and methods |
US6706008B2 (en) | 2001-03-06 | 2004-03-16 | Baxter International Inc. | Automated system and method for withdrawing compounds from blood |
US6884228B2 (en) | 2001-03-06 | 2005-04-26 | Baxter International Inc. | Automated system adaptable for use with different fluid circuits |
WO2004022111A1 (en) * | 2002-09-05 | 2004-03-18 | Mitra Medical Technology Ab | New composition use and method |
JP2008544847A (en) * | 2005-07-06 | 2008-12-11 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | Method for producing separation matrix |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3897985B2 (en) | Manufacture of an adsorption device using an adsorbent for reducing the concentration of fibrinogen and / or fibrin | |
JPH0557015A (en) | Adsorbent and sterilizing method therefor | |
JP3926573B2 (en) | Adsorbent manufacturing method for reducing the concentration of fibrinogen and / or fibrin, adsorbent and use of the adsorbent for the manufacture of an adsorber | |
EP0179420B1 (en) | Sterilization of adsorbent and column having improved storability including sterilized adsorbent for use in extracorporeal circulation treatment | |
JP3285441B2 (en) | Adsorbent for lowering plasma viscosity of vasoocclusive disease plasma and apparatus for lowering plasma viscosity | |
JPS6319214B2 (en) | ||
JPH0977790A (en) | Adsorbent for antibody to glycolipid | |
JPH0323182B2 (en) | ||
JPS63232845A (en) | Adsorbent for low-density lipoprotein and method for producing the same | |
JPS62191042A (en) | Blood coagulation factor viii adsorbent and method for purifying blood coagulation factor viii using same | |
JPH067430A (en) | Blood treating adsorbent | |
JP2578588B2 (en) | Method for improving storage stability of adsorption column for extracorporeal circulation treatment | |
JP3157026B2 (en) | Adsorbent for blood purification | |
JPS62224362A (en) | Adsorption column for extracorporeal remedy improved in storage stability | |
JPS59206045A (en) | Adsorbent for lipoprotein of low specific weight | |
JPS6256782B2 (en) | ||
JPS59139937A (en) | Low-density lipoprotein adsorbent | |
JP3181343B2 (en) | Method for producing adsorbent material for body fluid purification | |
JPH0547224B2 (en) | ||
JP4443309B2 (en) | Fibrinogen adsorbent III | |
JPH06233816A (en) | Hemocatharsis adsorbent | |
JPS62244442A (en) | Low specific gravity lipoprotein adsorbing material and its preparation | |
JPH0547223B2 (en) | ||
JPS60114340A (en) | Adsorbent for adsorption of low specific gravity lipoprotein | |
JPH05146509A (en) | Hemoglobin adsorbent |